Neuphoria Therapeutics Inc. (NEUP) stock
NEUPNasdaqPharmaceutical PreparationsFiscal year ends June 30
$2.55−0.03 (-1.16%)
Close on Nov 13, 2026Market cap $76.66KP/E –Yield –
Neuphoria Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Neuphoria Therapeutics's R&D Expenses for the twelve months ending Dec 31, 2025 was $9.85M, up 24.2% year over year. For fiscal 2025 it was $9.01M, down 4.4% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $9.01M | -4.4% |
| FY2024 | Jun 30, 2024 | $9.42M | -28.0% |
| FY2023 | Jun 30, 2023 | $13.07M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $697.72K | -59.8% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $3.79M | +99.2% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $3.75M | +21.2% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $1.62M | +34.8% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $1.74M | -14.6% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $1.90M | -38.4% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $3.10M | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $1.20M | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $2.03M | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $3.09M | – |
See a number that looks wrong?